NCT06386419 - A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions

Primary HypercholesterolemiaMixed Dyslipidemia

Interventions

DRUG

inclisiran

Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively

Trial Locations (7)

110029

Novartis Investigative Site, New Delhi

302039

Novartis Investigative Site, Jaipur

441108

Novartis Investigative Site, Nagpur

560099

Novartis Investigative Site, Bangalore

625107

Novartis Investigative Site, Madurai

632 004

Novartis Investigative Site, Vellore

700 020

Novartis Investigative Site, Kolkata